

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 04243822	A2	19920831	JP 1991-22643	19910124
PRAI	JP 1991-22643		19910124		

OS MARPAT 118:240923

AB Ca antagonists, for treatment of hypertension, angina pectoris, arrhythmia, brain circulatory diseases, etc., contain hesperidin, luteolin (derivs.) I (R1, R2 = H, glucosyl), caffeic acid, rosmarinic acid (mono-Me ester) II (R3 = H, Me), or schizotenuin A (III) as active ingredients. Flowers (9.9 kg) of Schizonepeta tenuifolia Briq. were extd. with MeOH and the ext. was processed to isolate hesperidin 186, luteolin 47, luteolin 7-O- β -D-glucopyranoside 175, caffeic acid 473, rosmarinic acid 1610, rosmarinic acid mono-Me ester 28, and III 573 mg. II inhibited nitrendipine binding with rabbit skeletal muscle membrane proteins with IC50 of 1.2×10^{-6} M. Corn starch 44, cryst. cellulose 40, CMC-Ca 5, light SiO2 0.5, Mg stearate 0.5, and hesperidin 10 g were mixed and made into granules.

L4 ANSWER 52 OF 55 CA COPYRIGHT 2006 ACS on STN

Full Text	Citing References
-----------	-------------------

AN 115:183950 CA

TI Preparation of amino acid conjugates as renal-selective prodrugs for the treatment of hypertension

IN Reitz, David B.; Koepke, John P.; Blaine, Edward H.; Schuh, Joseph R.; Manning, Robert E.; Smits, Glenn J.

PA G.D. Searle and Co., USA

SO PCT Int. Appl., 459 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9101724	A1	19910221	WO 1990-US4168	19900725
	W: CA, JP, KR, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, IT, LU, NL, SE				
	EP 484437	A1	19920513	EP 1990-912307	19900725
	R: AT, BE, CH, DE, DK, ES, FR, GB, IT, LI, LU, NL, SE				
	JP 04506967	T2	19921203	JP 1990-511397	19900725
	WO 9201667	A1	19920206	WO 1991-US611	19910128
	W: CA, JP, KR, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, NL, SE				
	US 2003220521	A1	20031127	US 2002-151211	20020520
	US 2004101523	A1	20040527	US 2003-689919	20031020
PRAI	US 1989-386527	A2	19890727		
	WO 1990-US4168	W	19900725		
	US 1994-280170	B1	19940725		
	US 1996-639493	B1	19960429		
	US 1999-444888	B1	19991122		
	US 2000-678015	A1	20001002		
	US 2002-151211	B1	20020520		

OS MARPAT 115:183950

AB Title compds., conjugates comprising a 1st residue and a 2nd residue connected by a cleavable bond, wherein the 1st residue is an inhibitor of the biosynthesis of an adrenergic neurotransmitter and the 2nd residue is cleaved by an enzyme located predominantly in the kidney, are prepd. 5-[(5-Butyl-2-pyridinyl)carbonyl]-L-glutamic acid hydrazide (prepn. given) in MeCN/H2O was treated with 2 equiv of 1M K2CO3 followed by Ac2O and

N

decreased after magnesium lithospermate B administration. Oral administration of lithospermic acid B also decreased these blood pressure values even though the effects were weaker than those of magnesium lithospermate B. However, rats given lithospermic acid, rosmarinic acid or caffeic acid showed no appreciable changes in systolic, mean or diastolic blood pressure throughout the exptl. period. Urinary excretion of both kallikrein and sodium was increased significantly in rats given magnesium lithospermate B or lithospermic acid B.

L4 ANSWER 50 OF 55 USPATFULL on STN

	Full Text	Citing References
AN	93:104947	USPATFULL
TI	Derivatives of tetrapeptides as CCK agonists	
IN	Shiosaki, Kazumi, Libertyville, IL, United States Nadzan, Alex M., Libertyville, IL, United States Kopecka, Hana, Vernon Hills, IL, United States Shue, Youe-Kong, Vernon Hills, IL, United States Holladay, Mark W., Vernon Hills, IL, United States Lin, Chun W., Wood Dale, IL, United States Nellans, Hugh N., Mundelein, IL, United States	
PA	Abbott Laboratories, Abbott Park, IL, United States (U.S. corporation)	
PI	US 5270302	19931214
AI	US 1991-713010	19910617 (7)
RLI	Continuation-in-part of Ser. No. <u>US 1990-541230</u> , filed on 20 Jun 1990, now abandoned which is a continuation-in-part of Ser. No. <u>US 1989-5673</u> , filed on 18 Dec 1989 which is a continuation-in-part of Ser. No. <u>US 1988-287955</u> , filed on 21 Dec 1988, now abandoned	
DT	Utility	
FS	Granted	
EXNAM	Primary Examiner: Lee, Lester L.	
LREP	Elder, Richard A., Crowley, Steven R., Weinstock, Steven F.	
CLMN	Number of Claims: 10	
ECL	Exemplary Claim: 1	
DRWN	2 Drawing Figure(s); 2 Drawing Page(s)	
LN.CNT	6175	
CAS INDEXING	IS AVAILABLE FOR THIS PATENT.	
AB	Selective and potent Type-A CCK receptor agonists of formula (I):	

X--Y--Z--Q.

(I)

or a pharmaceutically acceptable salt thereof, wherein,

X is selected from ##STR1## Y is selected from ##STR2## Z is ##STR3## and Q is ##STR4## or pharmaceutically-acceptable salts thereof, useful in the treatment of gastrointestinal disorders (including gallbladder disorders), central nervous system disorders, insulin-related disorders and pain, as well as in appetite regulation.

L4 ANSWER 51 OF 55 CA COPYRIGHT 2006 ACS on STN

	Full Text	Citing References
AN	118:240923	CA
TI	Calcium antagonists containing phenols	
IN	Kubo, Masayoshi; Morita, Osamu; Sasaki, Hiroshi; Sato, Shunji	
PA	Tsumura and Co., Japan	
SO	Jpn. Kokai Tokkyo Koho, 7 pp. CODEN: JKXXAF	
DT	Patent	
LA	Japanese	